<qa>  What is the potential for abortifacient effects?- Pregnant women are excluded from this study because AZD2014 is an mTORC12 inhibiting agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AZD2014, breastfeeding should be discontinued if the mother is treated with AZD2014. 